BACKGROUND: Meningeal carcinomatosis (MC) is a rare complication in breast cancer (BC) with no efficient modality of treatment yet found; overall survival (OS) generally did not exceed six months. We reviewed the experience of the University of Florence focusing on prognostic factors and MC survival. PATIENTS AND METHODS: We analyzed 33 patients treated for MC from BC between 2002 and 2010. RESULTS: Mean OS from MC diagnosis was 4.9 months. At survival analysis clinical stage emerged as the only statistical significant parameter (P = 0.009) among BC diagnosis features. Among MC diagnosis parameters, more than three metastases at diagnosis (P = 0.037), multimodality treatment (P = 0.014) and poor performance status (P = 0.003) reached the statistical significance. At multivariate analysis only performance status at MC diagnosis maintained the statistical significance (P = 0.0047; HR: 3.34; CI 95% 1.45-7.73). CONCLUSIONS: Our experience confirms that performance status is probably the most important prognostic factor in these patients. Multimodality approach is probably the best option.
BACKGROUND:Meningeal carcinomatosis (MC) is a rare complication in breast cancer (BC) with no efficient modality of treatment yet found; overall survival (OS) generally did not exceed six months. We reviewed the experience of the University of Florence focusing on prognostic factors and MC survival. PATIENTS AND METHODS: We analyzed 33 patients treated for MC from BC between 2002 and 2010. RESULTS: Mean OS from MC diagnosis was 4.9 months. At survival analysis clinical stage emerged as the only statistical significant parameter (P = 0.009) among BC diagnosis features. Among MC diagnosis parameters, more than three metastases at diagnosis (P = 0.037), multimodality treatment (P = 0.014) and poor performance status (P = 0.003) reached the statistical significance. At multivariate analysis only performance status at MC diagnosis maintained the statistical significance (P = 0.0047; HR: 3.34; CI 95% 1.45-7.73). CONCLUSIONS: Our experience confirms that performance status is probably the most important prognostic factor in these patients. Multimodality approach is probably the best option.
Authors: Anna Niwińska; Katarzyna Pogoda; Wojciech Michalski; Michał Kunkiel; Agnieszka Jagiełło-Gruszfeld Journal: J Neurooncol Date: 2018-02-12 Impact factor: 4.130
Authors: Emilie Le Rhun; Roberta Rudà; Patrick Devos; Khê Hoang-Xuan; Dieta Brandsma; Pedro Pérez Segura; Riccardo Soffietti; Michael Weller Journal: J Neurooncol Date: 2017-04-28 Impact factor: 4.130
Authors: Emilie Le Rhun; Andrew Kramar; Sophie Salingue; Marie Girot; Isabelle Rodrigues; Audrey Mailliez; Fahed Zairi; Edgar Bakhache; Yves Marie Robin; Sophie Taillibert; François Dubois; Jacques Bonneterre; Marc C Chamberlain Journal: J Neurooncol Date: 2014-01-28 Impact factor: 4.130
Authors: Sanziana Ri Schiopu; Gregor Habl; Matthias Haefner; Sonja Katayama; Klaus Herfarth; Juergen Debus; Florian Sterzing Journal: Cancer Manag Res Date: 2018-12-31 Impact factor: 3.989